Glenmark Pharmaceuticals On Wednesday Said It Has Received Tentative Approval From The Us Health Regulator For Its Generic Dapagliflozin And Saxagliptin Anti-Diabetes Tablets. The Approval Granted By The United States Food And Drug Administration (Usfda) To Glenmark Pharmaceuticals Inc., Usa, Is For The Strength Of 10 Mg/5 Mg Tablets, The Generic Version Of Qtern Tablets Of The Same Strength Of Astrazeneca Ab, The Company Said In A Statement.Citing Iqvia Sales Data For The 12-Month Period Ending February 2020, The Company Said Qtern Tablets, 10 Mg/5 Mg Had Achieved Annual Sales Of Approximately Usd 10.4 Million. Glenmark'S Current Portfolio Consists Of 162 Products Authorised For Distribution In The Us And 44 Abbreviated New Drug Applications Pending Approval With The Usfda, The Company Said.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!